Elevated Angiotensin 1–7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients with Heart Failure with Potential Link to COVID-19 Patients
|
By LabMedica International staff writers Posted on 04 Aug 2020 |
|
Image: Structure of the ACE2 (angiotensin-converting enzyme 2) protein (Photo courtesy of Wikimedia Commons)
A high ratio of angiotensin 1-7 to angiotensin II (Ang 1–7/Ang II ratio), was found to be an independent and incremental predictor of beneficial outcomes, higher survival rate, and decreased hospitalization duration for patients with heart failure and possibly in patients with cardiovascular complications due to COVID-19.
The enzyme ACE2 (angiotensin-converting enzyme 2) and the peptide Ang 1–7 are endogenous negative regulators of the renin-angiotensin system exerting cardioprotective effects in models of heart failure. ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into angiotensin (a vasodilator). It counters the activity of the related angiotensin-converting enzyme (ACE) by reducing the amount of angiotensin II. ACE2 is not only an enzyme but also a functional receptor on cell surfaces for both SARS-CoV (SARS coronavirus) and SARS-CoV-2 (COVID-19), and is highly expressed in the heart, testis, kidneys, and lungs, and shed into the plasma.
Since clinical trials have shown that recombinant human ACE2 markedly increased plasma Ang 1–7 and lowered Ang II levels, investigators at the University of Alberta (Edmonton, Canada) hypothesized that the dynamic state of this renin-angiotensin system protective arm could influence long-term outcomes in patients with heart failure.
To test this theory, the investigators examined circulating angiotensin peptide levels in the blood of 110 individuals who were experiencing heart failure due to a heart attack or stroke. Comprehensive circulating and equilibrium levels of plasma angiotensin peptide profiles were assessed using novel liquid chromatography-mass spectrometry/mass spectroscopy techniques.
Results revealed that circulating and equilibrium angiotensin peptide levels strongly correlated in the patient group. Elevated Ang 1–7/Ang II ratios were associated with improved survival and lower hospitalization duration. In contrast, individual Ang 1–7 and Ang II peptide levels failed to predict all-cause mortality or hospitalization duration in the patient group.
Senior author Dr. Gavin Oudit, professor of cardiology at the University of Alberta, said, "The discovery of the ratio test highlights the bridge between cardiovascular disease and COVID-19 and the pivotal role ACE2 plays in both diseases. In heart failure patients, when your ACE2 is working well, your mortality is much lower, hospitalization is reduced. Now we need to see the parallels in patients with COVID-19. We are fortunate that we have the understanding of ACE2, and we have both the research and therapeutic tools to target this pathway for patients with heart failure, and also now patients with COVID-19. The crisis is an opportunity to better help all of our patients."
The study was published in the June 25, 2020, online edition of the journal Circulation: Heart Failure.
Related Links:
University of Alberta
The enzyme ACE2 (angiotensin-converting enzyme 2) and the peptide Ang 1–7 are endogenous negative regulators of the renin-angiotensin system exerting cardioprotective effects in models of heart failure. ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into angiotensin (a vasodilator). It counters the activity of the related angiotensin-converting enzyme (ACE) by reducing the amount of angiotensin II. ACE2 is not only an enzyme but also a functional receptor on cell surfaces for both SARS-CoV (SARS coronavirus) and SARS-CoV-2 (COVID-19), and is highly expressed in the heart, testis, kidneys, and lungs, and shed into the plasma.
Since clinical trials have shown that recombinant human ACE2 markedly increased plasma Ang 1–7 and lowered Ang II levels, investigators at the University of Alberta (Edmonton, Canada) hypothesized that the dynamic state of this renin-angiotensin system protective arm could influence long-term outcomes in patients with heart failure.
To test this theory, the investigators examined circulating angiotensin peptide levels in the blood of 110 individuals who were experiencing heart failure due to a heart attack or stroke. Comprehensive circulating and equilibrium levels of plasma angiotensin peptide profiles were assessed using novel liquid chromatography-mass spectrometry/mass spectroscopy techniques.
Results revealed that circulating and equilibrium angiotensin peptide levels strongly correlated in the patient group. Elevated Ang 1–7/Ang II ratios were associated with improved survival and lower hospitalization duration. In contrast, individual Ang 1–7 and Ang II peptide levels failed to predict all-cause mortality or hospitalization duration in the patient group.
Senior author Dr. Gavin Oudit, professor of cardiology at the University of Alberta, said, "The discovery of the ratio test highlights the bridge between cardiovascular disease and COVID-19 and the pivotal role ACE2 plays in both diseases. In heart failure patients, when your ACE2 is working well, your mortality is much lower, hospitalization is reduced. Now we need to see the parallels in patients with COVID-19. We are fortunate that we have the understanding of ACE2, and we have both the research and therapeutic tools to target this pathway for patients with heart failure, and also now patients with COVID-19. The crisis is an opportunity to better help all of our patients."
The study was published in the June 25, 2020, online edition of the journal Circulation: Heart Failure.
Related Links:
University of Alberta
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Latest Molecular Diagnostics News
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
